The Manila Times2d
GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia
Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...
pharmaphorum2d
After FDA setback, Ipsen gets first OK for rare disease drug palovarotene
an ALK2 inhibitor. FOP is caused by a mutation in the gene for ALK2, which is known as ACVR1.